CHARENTON-LE-PONT, France,
August 27, 2010 /PRNewswire/ --
- A Very Good First Half
- Sharp Increase in Revenue: up 15.8%
- High Contribution Margin Maintained, at 18.0% of Revenue
- Adjusted Earnings per Share: up 17.6%
- Strong Increase in Free Cash Flow: up 72%
The 2010 interim financial statements were approved by the Board
of Directors of Essilor International on August 26, 2010. These financial statements have
been audited and the Statutory Auditors have issued an unqualified
opinion thereon.
EUR millions First-half 2010 First-half 2009 % Change
Revenue 1,926.8 1,663.4 +15.8%
Contribution margin(1) 347.5 301.8(4) +15.2%
% of revenue 18.0% 18.1% -
Profit attributable to equity 197.5 200.1 -1.3%
holders of Essilor
International
Adjusted attributable 238.8 200.1 +19.3%
profit(2)
Earnings per share (in EUR) 0.94 0.97 -2.7%
Adjusted earnings per share 1.14 0.97 +17.6%
(in EUR)(2)
Free cash flow(3) 165 96 +72%
(1) Operating profit before compensation costs of share-based
payments, restructuring costs, other income and expense, and
goodwill impairment.
(2) Adjusted for the EUR41.3
million net of tax provision set aside for the fine imposed
by the BKA, the German antitrust authority, which the Company has
appealed.
(3) Net cash from operating activities less purchases of
property, plant and equipment and intangible assets, according to
the IFRS consolidated cash flow statement.
(4) Adjusted for EUR0.9 million in
non-capitalized costs related to bolt-on acquisitions (application
of revised IFRS 3).
In an ophthalmic optics market that is slowly but steadily
improving, Essilor continued to increase its global market share by
leveraging its innovative products and accelerating the deployment
of its targeted acquisitions strategy. For the period, the Company
posted revenue growth of 5.9% excluding the currency effect and
strategic acquisitions, in line with its full-year objective.
Essilor also enhanced its competitiveness through ongoing programs
to optimize the production base and develop new services for
eyecare professionals.
First-half highlights
- Integration of FGXI, the world leader in non-prescription
reading glasses, and Signet Armorlite, the exclusive manufacturer and
distributor of Kodak-brand lenses. Overall, these acquisitions were
accretive to first-half consolidated earnings.
- Successful new product launches, of which the Varilux Physio(R)
2.0 lens in Europe and the United States, the Xperio(TM) polarized lens
in Europe, and lenses produced using Eyecode(TM) technology around the
world.
- An increase in unit sales, reflecting the ramp-up of the
Company's strategy of developing the mid-range product segment and
rapid growth in emerging markets.
- Accelerated deployment of the acquisitions strategy with 13 new
partnerships that extend Essilor's geographical coverage.
- High operating margin remained (contribution margin 18% of
revenue) thanks to ongoing gains in operating efficiency.
- Sharp increase in adjusted earnings per share.
- A strong increase in net cash flow and a solid balance sheet.
Outlook
The very good first-half results support Essilor's major
strategic choices. During the second half, in a still fragile
business recovery, Essilor will continue to implement its growth
strategy, based on new products, geographic expansion, bolt-on
acquisitions and the mid-segment. For 2010, the Company confirms
its objectives of revenue growth of 5% to 7% excluding the currency
effect and strategic acquisitions, and a stable contribution margin
excluding strategic acquisitions and changes in IFRS.
Moreover, following the sale of its stake in Sperian Protection,
the Company will recognize an estimated EUR27-million consolidated capital gain in the
second half.
------------------------
An analysts meeting will be held today, August 27, at 9:30
a.m. Paris time.
The meeting will be available live and recorded for later
listening at:
http://hosting.3sens.com/Essilor/20100827-FC6C8EAD/en/
The presentation will be webcast at:
http://www.essilor.com/-results-presentations-
Regulatory Information
The interim financial report is available at
http://www.essilor.com or by clicking on:
http://www.essilor.com/-Reports-#interim
------------------------
Future event:
Third-quarter revenue will be released on Friday, October 22, 2010.
------------------------
The world leader in ophthalmic optical products, Essilor International
researches, develops, manufactures and markets around the world a wide
range of lenses to improve and protect eyesight. Its flagship brands are
Varilux(R), Crizal(R), Essilor(R), Definity(R) and Xperio(TM).
Based in France, the company reported consolidated revenue of more than
EUR3.2 billion in 2009, with 34,700 employees and operations in 100
countries.
For more information, please visit http://www.essilor.com.
The Essilor share trades on the NYSE Euronext Paris market and is
included in the CAC 40 index.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA;
Bloomberg: EI:FP.
MANAGEMENT REPORT
The 2009 financial statements have been adjusted following the
expensing of acquisition-related costs in accordance with revised
IFRS 3.
REVENUE UP 11.8% AT CONSTANT EXCHANGE RATES
Revenue by division and by region
(in EUR millions) H1 2010 H1 2009 % Change Like-for-like Contribution
(reported) growth from
acquisitions*
Lenses and 1,786.9 1,613.6 +10.7% +2.5% +4.1%
Optical
Instruments
Europe 707.6 665.1 +6.4% +1.4% +4.1%
North America 776.4 718.1 +8.1% +1.0% +3.9%
Asia-Pacific & 214.3 170.1 +26.0% +8.0% +4.8%
Africa
Latin America 88.6 60.3 +47.1% +16.6% +5.0%
Equipment 60.2 49.8 +20.8% +8.8% +12.1%
Readers 79.7 - N/M N/M N/M
TOTAL 1,926.8 1,663.4 +15.8% +2.7% +9.1%
* Revenue from Signet Armorlite has been allocated by
region.
Revenue rose 15.8% to EUR1,926.8
million in first-half 2010. Excluding FGXI and Signet,
revenue growth stood at 10%.
- Like-for-like growth in first-half revenue came to 2.7%, which
included increases of 2.5% in the first quarter and 2.9% in the second.
This reflected growth of 2.5% in the Optical Lenses business and 8.8%
in the Equipment business.
- The 9.1% contribution from acquisitions corresponds to the
bolt-on acquisitions carried out in 2009 and first-half 2010, for 3.2%,
and the contribution of FGXI and Signet Armorlite, consolidated from
March 12 and April 1, 2010 respectively.
- The positive currency effect of 4% reflects the euro's decline against
all the other currencies and particularly the Brazilian real,
the Canadian dollar and the US dollar.
Performance by division
Lenses and Optical Instruments
Revenue growth was driven by an increase in sales volumes in all regions.
- In Europe, where performances still vary considerably from
one country to another, sales progressed overall by 1.4% like-for-like.
France maintained strong momentum thanks to its multi-network strategy
and business picked up in the Netherlands, but remained disappointing
in Germany and Austria. Benefiting from Russia's rapid development,
the Eastern European countries returned to growth.
- Growth leveled off in North America (up 1.0% like-for-like). In
the United States, all distribution channels contributed to growth in
volumes, with a significant increase reported in sales of Xperio
polarized lenses. Operating problems affected performance in Canada,
in an already challenging environment.
- In Asia, like-for-like growth of 8.0% was led by emerging
markets. Essilor continued its rapid expansion in India, where it
gained market share during the period, as well as in the ASEAN
countries, particularly Thailand and Indonesia. Business in China was
stimulated by improvements in the product mix, while sales contracted
in Australia and New Zealand in a difficult market environment.
- Countries in Latin America recorded significant growth in
the first half, with revenue for the region up 16.6% like-for-like. In
Brazil, the mid-range segment benefited from an increase in volumes and
higher demand for anti-reflective lenses, and Mexico and Argentina both
reported very strong growth.
Equipment
- The Equipment division began to recover sharply in the first
half of 2010, with revenue up 8.8% like-for-like excluding intragroup
sales. Satisloh sales were particularly robust in the area of
consumables and digital surfacing machines. Business is developing
rapidly in Asia, particularly in China where Satisloh now has a
dedicated product offering.
Readers
- Recently created following the acquisition of FGX International, the
Readers division[1] performed very well. The second
quarter saw particularly strong sales of sunglasses, which dominate
demand at that time of year.
Second quarter: continued recovery in growth
Revenue Q2 2010 Q2 2009 % Change Like-for-like Contribution
growth from
(in EUR millions) as acquisitions*
reported
Lenses and Optical 923.0 797.7 +15.7% +2.3% +5.2%
Instruments
Europe 362.3 335.1 +8.1% +2.1% +5.0%
North America 400.7 345.7 +15.9% -0.2% +5.2%
Asia-Pacific & 111.2 84.5 +31.6% +7.5% +4.3%
Africa
Latin America 48.8 32.5 +50.1% +17.6% +6.2%
Equipment 36.6 25.4 +44.2% +20.5% +23.7%
Readers 61.3 - N/M N/M N/M
TOTAL 1,020.9 823.1 +24.0% +2.9% +13.2%
* Revenue from Signet Armorlite has been allocated by region
Consolidated revenue for the second quarter alone stood at
EUR1,020.9 million, up 24%
year-on-year as reported and 2.9% like-for-like. The integration of
FGXI and Signet, as well as new partnerships, brought the
contribution from acquisitions to a high 13.2%. All currencies
contributed to the significant 7.9% positive currency effect.
The trends observed during the quarter varied between regions,
with:
- A slight improvement in Europe.
- Stable demand in the United States and operating problems in Canada.
- Continued sharp growth in Asia, except for Australia and Japan.
- Very strong demand in Latin America.
- A sharp recovery in the Equipment business.
13 new partnerships and 2 strategic acquisitions in first-half
2010
During the first half of 2010, Essilor acquired or increased its
holding in 13 companies, representing additional revenue of around
EUR80 million. Transactions were
carried out in all regions:
- In the United States, Essilor of America acquired a stake in
two prescription laboratories- Hawkins in Kansas ($4.5 million in
revenue) and Epic Labs in Minnesota ($3 million). EOA also acquired the
assets of Custom Optical (Georgia, $2.5 million). Nikon-Essilor
increased its stake in the Encore prescription laboratory (Connecticut,
$4 million) through its US subsidiary.
- In Canada, Essilor acquired a majority stake in Cascade, a
prescription laboratory in the province of British Columbia (C$6
million), and in Econo-Optic, a laboratory based in New Brunswick
(C$0.7 million).
- In Brazil, the Company acquired an interest in Ceditop, a
prescription laboratory and distributor in the state of Rio Grande do
Sul, with annual revenue of around EUR3.5 million (BRL8 million).
- In China, a majority stake was acquired in ILT Danyang,
which produces lenses for both the domestic market and for export.
- In Singapore, the Company acquired Visitech, a distributor
that generates around EUR0.7 million in annual revenue.
- In Taiwan, a majority stake was acquired in SMJ, a
prescription laboratory and distributor with EUR1.6 million in revenue.
- In the United Arab Emirates, Essilor become the majority
shareholder of Ghanada Opticals, a prescription laboratory based in Abu
Dhabi, which serves the United Arab Emirates and the other Gulf states
and generates EUR2 million in revenue.
- In Australia, Essilor became a 70% partner in a joint venture with
Luxottica, which owns the Eyebiz laboratory.
- In the Equipment division, the Company acquired a 60% interest in DAC
Vision, one of the world's leading manufacturers of
consumable supplies for surfacing, coating and mounting lenses, which
generates around EUR30 million in revenue, mainly in France and the
United States.
Since the beginning of the year, Essilor has also made two
strategic acquisitions: FGX International, the North American
leader in non-prescription reading glasses with $259 million in 2009 revenue, and California-based Signet Armorlite, one of the
largest independent manufacturers of ophthalmic lenses and the
exclusive producer of Kodak-brand lenses, with 2009 revenue of
$115 million.
CONTRIBUTION MARGIN: 18.0%
Contribution from operations up 15.2% to EUR347.5 million, or 18% of
revenue
(in EUR millions) First-half 2010 First-half First-half
2010 2009
excl. FGXI
and Signet
Armorlite
Gross margin 1,068.8 1,015.8 930.7
As a % of revenue 55.5% 55.5% 56.0%
Operating expenses 721.2 684.7 628.9
Contribution from operations 347.5 331.0 301.8
(1)
18.0% 18.1% 18.1%
As a % of revenue
(1) Operating profit before compensation costs of share-based
payments, restructuring costs, other income and expense, and
goodwill impairment.
Gross margin up 14.8% to EUR1,068.8
million (up 9.1% excluding FGXI and Signet Armorlite)
In first-half 2010, gross margin (revenue less cost of sales,
expressed as a percentage of revenue) stood at 55.5%, compared with
56.0% in first-half 2009. The decrease is mainly due to the
dilutive effect of bolt-on acquisitions and the ramp-up of
mid-range networks.
Operating expenses up 14.7% to EUR721.2
million (up 8.9% excluding FGXI and Signet Armorlite)
Operating expenses in the first half accounted for 37.4% of
consolidated revenue, versus 37.8% in the prior-year period, when
they amounted to EUR628.9
million.
Operating expenses comprised:
- R&D and engineering costs of EUR78.4 million, up 4.7% over first-half
2009.
- Selling and distribution costs of EUR421.7 million, versus EUR353.4
million in the prior-year period, representing an increase of 19.3%
(12.9% excluding FGXI and Signet Armorlite) and coming to 21.9% of
revenue compared with 21.2% in first-half 2009.
- Other operating expenses of EUR221.2 million, representing
an increase of 10.3% (3.5% excluding FGXI and Signet Armorlite) and
11.5% of consolidated revenue versus 13.2% in first-half 2009.
Excluding FGXI and Signet Armorlite, the contribution margin
rose 9.7% to EUR331 million and
represented 18.1% of revenue, as in first-half 2009.
This performance reflects the Company's ability to integrate
acquisitions, drive further productivity gains and diligently
manage its operating expenses.
ADJUSTED EPS UP 17.6% TO EUR1.14
Operating profit up 1.0% to EUR281.2
million (up 15.9% excluding BKA provision)
"Other income and expenses from operations" and "Gains and
losses on asset disposals" together represented a net expense of
EUR66.3 million (compared with
EUR23.4 million in first-half 2009).
The increase reflects:
- Virtually unchanged compensation costs on stock options,
performance share grants and employee stock ownership plans of EUR10.1
million, versus EUR9.7 million in first-half 2009.
- Restructuring costs of EUR12.5 million, versus EUR6.5 million in the
prior-year period.
- A EUR41.5 million provision set aside for the fine imposed by Germany's
competition authorities, the Bundeskartellamt (BKA). Essilor has
lodged two appeals against the BKA's decision, which suspend payment of
the fine (see Note 10 of the financial statements).
Operating profit represented 14.6% of consolidated revenue,
compared with 16.7% in first-half 2009.
Finance costs and other financial income and expenses, net: net
expense of EUR6.2 million
Finance costs and other financial income and expenses
represented a net expense of EUR6.2
million compared with EUR5.3
million in first-half 2009, reflecting an increase in
average debt partially offset by a decrease in finance costs.
Profit attributable to equity holders of Essilor International
down 1.3% to EUR197.5 million (up
19.3% excluding BKA provision)
Net profit totaled EUR202.9
million, versus EUR204.8
million in first-half 2009. It comprised:
- Income tax expense of EUR88.8 million. The 32.3% effective
tax rate (28.1% excluding BKA provision) compared with a 28.9% rate for
first-half 2009.
- The share of profit from associates - VisionWeb, Sperian
Protection and Transitions - which amounted to EUR16.7 million, versus
EUR10.7 million in the prior-year period. Earnings were up for both
Transitions (EUR14.2 million versus EUR9.8 million in first-half 2009)
and Sperian Protection (EUR2.5 million versus EUR0.9 million).
Profit attributable to equity holders of the parent amounted to
EUR197.5 million, down 1.3%, and
earnings per share stood at EUR0.94,
down 2.7%.
Excluding the BKA provision, attributable profit rose 19.3% to
EUR238.8 million and earnings per
share climbed 17.6% to EUR1.14.
FREE CASH FLOW UP 72%
The Company' high profitability and robust performance enabled
it to pursue an ambitious program of industrial and financial
investment (acquisitions and share buybacks) and to increase
dividends.
Investments
Capital expenditure net of divestments totaled EUR54 million or 2.8% of consolidated
revenue.
Financial investments net of disposals amounted to EUR563 million, which included EUR485 million related to acquisitions, mainly
FGXI and Signet Armorlite.
Transactions involving Essilor shares amounted to EUR182 million. These included the buyback of 4.1
million shares, as well as employee share grants and the conversion
of OCEANE bonds.
Working capital requirement
The change in working capital requirement amounted to
EUR106 million, relatively unchanged
from first-half 2009, despite the seasonal impact of annual
discount payments to customers, which are generally concentrated in
the first half.
Inventories amounted to EUR626
million at June 30, 2010,
compared with EUR486 million at
year-end 2009, an increase of 28.8%. At comparable scope of
consolidation and exchange rates, the increase was 6.8%.
Free cash flow and change in net debt
At EUR165 million, free cash
flow[2] was up 72% compared with first-half 2009.
At June 30, 2010, net debt was up
EUR731 million to EUR638 million,
compared with net cash of EUR93
million at December 31, 2009,
for gearing of 21.6%.
Cash Flow Statement
(in EUR millions)
Net cash from operations 329 Purchases of property, 58
(before WCR) plant and equipment
Proceeds from employee share 40 Change in WCR 106
issue
Reported change in net debt 731 Dividends 147
Financial investments net 563
of disposals*
Treasury stock 182
Other 44
* Of which EUR107 million in
acquired financial debt
SIGNIFICANT EVENTS SINCE THE END OF THE FIRST HALF
Acquisitions
Since July 1, two new partnerships
have been created in the United
States:
- Essilor of America acquired a majority stake in Gulf States,
a prescription laboratory based in Louisiana that generates $3
million in revenue.
- Nikon Optical US, a Nikon-Essilor subsidiary, acquired a majority
interest in Colorado-based Pasch, which generates $3.9 million in
revenue.
Divestment of Sperian Protection shares
Essilor sold its long-standing 15% stake in Sperian Protection
to Honeywell on August 9, 2010. The
asset's net realizable value is estimated at nearly EUR132 million. The consolidated capital gain
from the sale (estimated at approximately EUR27 million) will be recognized in the
Company's second-half 2010 accounts.
Redemption of OCEANE convertible bonds
On July 2, Essilor redeemed at
maturity all the 2003 OCEANE bonds that had not yet been converted.
These bonds were previously traded on the NYSE-Euronext Paris
exchange under ISIN code FR0000189276.
Ongoing share buybacks
Since June 30, Essilor has pursued
its share buyback program. More than 700,000 shares with a total
value of EUR33.7 million have been
bought back on the market.
Related party transactions / Risks and contingencies
In first-half 2010, the nature of transactions with companies
consolidated by the proportionate or equity method was not
significantly different from the description in the 2009
Registration Document.
Similarly, risks and contingencies to which the Company is
exposed in the months ahead are generally in line with the analysis
presented in Chapter 4 of the Registration Document.
---------------------------------
[1] The Readers business encompasses the production,
distribution and sale of non-prescription glasses. The division's
end customers are retailers, who sell the products on to
consumers.
[2]Net cash from operating activities less purchases of
property, plant and equipment and intangible assets, according to
the IFRS consolidated cash flow statement.
Investor Relations and Financial Communications
Veronique Gillet - Sebastien Leroy
Phone: +33-1-49-77-42-16
http://www.essilor.com
